All News

New data showed that treatment with hydroxychloroquine was associated with increased mortality in hospitalized patients with COVID-19. 

Women and older adults are underrepresented in clinical trials evaluating cholesterol medications, according to a new study published in JAMA Network Open.

Migraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.

Officials with the FDA have approved Octapharma’s investigational new drug (IND) application for intravenous immune globulin (IVIG) (Human, Octagam 10%) therapy.

A close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.

Here's a roundup of the latest coronavirus-related news.

AstraZeneca has received funds exceeding $1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford’s coronavirus disease 2019 (COVID-19) vaccine candidate.

Supplementation during pregnancy can have potential positive health outcomes for offspring.

The US Department of Health & Human Services partners with Phlow Corporation team to prevent drug shortages during the current pandemic and in future public health emergencies.

A new guidance from the US Department of Health & Human Services (HHS) paves the way for pharmacists nationwide to administer coronavirus disease 2019 (COVID-19) tests.

Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.

A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV. 

Monitoring and controlling heart disease may be crucial in supporting cognitive health later in life.

Atezolizumab demonstrated a significant overall survival benefit in individuals with high PD-L1 expression compared with chemotherapy.

The US Department of Health & Human Services has left it up to state health departments to decide how to distribute remdesivir to hospitals.

Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).

Community pharmacies are ideally positioned to support reopening efforts and recovery plans amid the coronavirus disease 2019 pandemic. 

Rucaparib is the first PARP inhibitor that has been approved in a prostate cancer setting.

Moderna’s coronavirus disease 2019 vaccine candidate, mRNA-1273, showed promise in interim data from its phase 1 study.

"I have to admit that in all 39 years of my career as a community pharmacist, I have never seen a drug that was the center of such intense political discussion."

A new study found that the use of PCSK9 inhibitors with maximally tolerated statins does not negatively affect the mental cognition of patients.

New digital health products are providing more insight into data and the opportunity for real-time patient interaction.

Heart disease is so common among Americans that it claims 1 life every 37 seconds.

A presentation from the 2020 PQA Annual Meeting examined how employers can engage in improving quality of care for those dependent on opioids.

Pharmacists are often the most accessible health care professionals, which is why a lack of access to pharmacies can have a detrimental effect on patients, especially those with chronic conditions. 

Thank you to pharmacy staff on the front lines. 

Investigators are looking for a new way to improve upon a 100-year-old vaccine.

On Tuesday, California Governor Gavin Newsom granted California pharmacists the ability to order and administer coronavirus disease 2019 (COVID-19) tests.

A presentation from the 2020 PQA Annual Meeting discussed the emerging focus on social determinants of health within the industry and how pharmacists can address the issue.

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.